A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies.
brain tumors
central nervous system
counseling
distress
physician
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
7
8
2019
Statut:
ppublish
Résumé
Unaddressed high distress leads to noncompliance with treatment, negatively affects quality of life, and may also have a negative impact on the prognosis of cancer patients. Patients with brain tumors have higher levels of distress than the general population and hence we hypothesize that even routine visits during adjuvant treatment or follow-up are likely to be stressful. This analysis was performed to identify the incidence of distress and factors affecting it. This was an audit of 84 consecutive patients seen in an adult neuro-medical oncology outpatient department who were either receiving adjuvant chemotherapy or were on follow-up. Distress screening with the National Comprehensive Cancer Network (NCCN) distress thermometer was performed. Patients in whom distress was scored as 4 or above were considered as having high distress. Descriptive statistics and logistic regression analysis were performed to identify factors affecting distress. The median age of the cohort was 40 years (interquartile range, 28.3 to 50 years). Actionable distress defined as a distress score of 4 or more was seen in 52 patients (61.9%, 95% CI 51.2% to 71.5%). Presence of physical deficit (odds ratio [OR] = 3.412, A high proportion of brain tumor patients either on adjuvant chemotherapy or on follow-up have high distress levels that need to be addressed even during follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Unaddressed high distress leads to noncompliance with treatment, negatively affects quality of life, and may also have a negative impact on the prognosis of cancer patients. Patients with brain tumors have higher levels of distress than the general population and hence we hypothesize that even routine visits during adjuvant treatment or follow-up are likely to be stressful. This analysis was performed to identify the incidence of distress and factors affecting it.
METHODS
METHODS
This was an audit of 84 consecutive patients seen in an adult neuro-medical oncology outpatient department who were either receiving adjuvant chemotherapy or were on follow-up. Distress screening with the National Comprehensive Cancer Network (NCCN) distress thermometer was performed. Patients in whom distress was scored as 4 or above were considered as having high distress. Descriptive statistics and logistic regression analysis were performed to identify factors affecting distress.
RESULTS
RESULTS
The median age of the cohort was 40 years (interquartile range, 28.3 to 50 years). Actionable distress defined as a distress score of 4 or more was seen in 52 patients (61.9%, 95% CI 51.2% to 71.5%). Presence of physical deficit (odds ratio [OR] = 3.412,
CONCLUSION
CONCLUSIONS
A high proportion of brain tumor patients either on adjuvant chemotherapy or on follow-up have high distress levels that need to be addressed even during follow-up.
Identifiants
pubmed: 31386081
doi: 10.1093/nop/npy046
pii: npy046
pmc: PMC6660816
doi:
Types de publication
Journal Article
Langues
eng
Pagination
305-310Références
Psychooncology. 2001 Jan-Feb;10(1):19-28
pubmed: 11180574
Crit Rev Oncol Hematol. 2003 Apr;46(1):5-16
pubmed: 12672514
Support Care Cancer. 2007 Jan;15(1):73-9
pubmed: 16816961
Psychooncology. 2007 Jun;16(6):582-6
pubmed: 17109494
Psychooncology. 2008 Jun;17(6):621-5
pubmed: 17973236
J Neurooncol. 2008 Dec;90(3):321-8
pubmed: 18704269
J Cancer Surviv. 2008 Dec;2(4):269-74
pubmed: 18958627
J Neurooncol. 2009 Aug;94(1):103-10
pubmed: 19255726
Support Care Cancer. 2009 Jul;17(7):793-9
pubmed: 19421789
Int J Oral Maxillofac Surg. 2009 Sep;38(9):955-9
pubmed: 19446438
J Clin Oncol. 2009 Aug 1;27(22):3712-22
pubmed: 19470928
J Neurooncol. 2009 Dec;95(3):413-419
pubmed: 19548070
J Natl Compr Canc Netw. 2003 Jul;1(3):344-74
pubmed: 19761069
Psychooncology. 2011 Jun;20(6):623-30
pubmed: 21449043
Curr Oncol. 2011 Oct;18(5):208-10
pubmed: 21980246
Neuro Oncol. 2013 May;15(5):635-43
pubmed: 23444258
Cancer. 2013 Aug 1;119(15):2796-806
pubmed: 23661311
CNS Oncol. 2014 Jan;3(1):37-47
pubmed: 25054899
Psychooncology. 2014 Mar;23(3):241-50
pubmed: 25160838
Psychooncology. 2015 May;24(5):540-7
pubmed: 25251838
Psychooncology. 2015 Jul;24(7):832-4
pubmed: 25534299
Ann Rehabil Med. 2014 Dec;38(6):726-33
pubmed: 25566470
Patient Educ Couns. 2015 Apr;98(4):525-32
pubmed: 25638306
Front Oncol. 2015 Sep 22;5:203
pubmed: 26442215
Lancet Oncol. 2017 Jun;18(6):e330-e340
pubmed: 28593859
J Natl Compr Canc Netw. 2017 Oct;15(10):1224-1233
pubmed: 28982748
J Glob Oncol. 2018 Sep;4:1-10
pubmed: 30241232
Anticancer Res. 1996 Mar-Apr;16(2):995-9
pubmed: 8687166